News and Trends 12 Dec 2022
Enterome completes patient enrollment for recurrent glioblastoma study
Enterome has completed patient enrollment in its phase 2 clinical trial (ROSALIE) evaluating its lead OncoMimics candidate, EO2401, in combination with an immune checkpoint inhibitor (nivolumab) +/- an anti-VEGF therapy…